ePrints

The use of real-world evidence for evaluating anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration

Lookup NU author(s): James Talks

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2019 Randomized controlled trials are the gold standard in medical research, providing evidence of the efficacy of a treatment in well-defined patient populations. By contrast, real-world studies explore the effectiveness of treatments in routine clinical practice, often with diverse patient populations. Although both randomized controlled trials and real-world studies contribute to the understanding of the benefits and risks of therapies, they generate different types of data and serve complementary purposes. Real-world studies evaluating the management of neovascular age-related macular degeneration have shown that visual outcomes achieved with anti–vascular endothelial growth factor in clinical practice often differ from those derived from clinical trials, highlighting the importance of assessing such outcomes in real-world studies. Benefits include finding variations in treatment provision, leading to: service improvements; the understanding of the need for continued and higher than previously provided treatment frequency; and new treatment regimens such as treat-and-extend. There is potential for the scope of real-world studies to be expanded to include other patient outcomes, such as quality of life, thus providing decision-makers with additional information to complement the data collected in randomized controlled trials. Physicians, patients, and regulators stand to gain much from further development and the conduct of real-world studies. We provide an overview of the importance of real-world evidence in the management of neovascular age-related macular degeneration with anti–vascular endothelial growth factor therapy, describe sources of real-world evidence, and assess the relative strengths and limitations of randomized controlled trials and real-world studies.

Publication metadata

Author(s): Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, Mitchell P, Wong TY, Korobelnik J-F

Publication type: Article

Publication status: Published

Journal: Survey of Ophthalmology

Year: 2019

Volume: 64

Issue: 5

Pages: 707-719

Print publication date: 01/09/2019

Online publication date: 22/02/2019

Acceptance date: 13/02/2019

ISSN (print): 0039-6257

ISSN (electronic): 1879-3304

Publisher: Elsevier USA

URL: https://doi.org/10.1016/j.survophthal.2019.02.008

DOI: 10.1016/j.survophthal.2019.02.008

Altmetrics

Share